Researchers from the Gwangju Institute of Science and Technology (GIST) have made a groundbreaking discovery in the fight against liver disease, particularly metabolic dysfunction-associated steatotic liver disease (MASLD) and its more severe form, metabolic dysfunction-associated steatohepatitis (MASH).
This significant health concern, characterized by fat accumulation in the liver leading to inflammation and potential fibrosis, has been a growing threat, urgently calling for effective treatments.
Enter compound 11c, a novel peripheral 5HT2A antagonist, which represents a significant step forward in the treatment of these metabolic disorders.
Published in Nature Communications, this research showcases the promising efficacy and safety profile of compound 11c in preclinical models, marking it as a leading advancement in liver disease treatment.
The development of compound 11c began with the screening of a drug library, leading to the identification of Desloratadine as a potential candidate.
Through meticulous analysis and molecular docking techniques, the research team transformed Desloratadine into the highly potent compound 11c.
This compound not only exhibits a strong biological activity but also demonstrates a reduction in inflammatory and fibrosis markers, indicating its potential as an anti-inflammatory and anti-fibrotic treatment.
“Compound 11c’s promising attributes extend to its safety profile, showing stability in hepatocytes and plasma, minimal cytotoxicity, and low inhibition of cytochrome P450,” explains Dr. Haushabhau Shivaji Pagire, senior researcher at GIST.
With over 60% oral bioavailability, compound 11c emerges as a compelling oral treatment candidate for MASLD and MASH, diseases currently driving the need for liver transplants.
The urgency for new treatments is underscored by the fact that obesity-associated MASH ranks as the third leading cause of liver transplantation and is on track to surpass hepatitis C in this regard.
The discovery of compound 11c opens up new possibilities for managing liver disease, potentially transforming the landscape of treatment and offering hope to millions affected worldwide.
As compound 11c progresses to the Phase I clinical trial, the medical community and patients alike watch eagerly. This next step is crucial in determining the compound’s effectiveness in humans and could significantly shift how metabolic liver disorders are treated.
With the potential to change the course of liver disease treatment, compound 11c stands at the forefront of a promising new era in medical science.
If you care about liver health, please read studies about a diet that can treat fatty liver disease and obesity, and coffee drinkers may halve their risk of liver cancer.
For more information about liver health, please see recent studies that anti-inflammatory diet could help prevent fatty liver disease, and results showing vitamin D could help prevent non-alcoholic fatty liver disease.
The research findings can be found in Nature Communications.
Copyright © 2024 Knowridge Science Report. All rights reserved.
